Cargando…

Urinary Monocyte Chemoattractant Protein-1 in Patients With Alport Syndrome

Detalles Bibliográficos
Autores principales:	Kashtan, Clifford, Schachter, Asher, Klickstein, Lloyd, Liu, Xin, Jennings, Lori, Finkel, Nancy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091606/ https://www.ncbi.nlm.nih.gov/pubmed/35571002 http://dx.doi.org/10.1016/j.ekir.2022.01.1052

Ejemplares similares

Alport syndrome: facts and opinions
por: Kashtan, Clifford
Publicado: (2017)

Multidisciplinary Management of Alport Syndrome: Current Perspectives
por: Kashtan, Clifford
Publicado: (2021)

Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation
por: Kashtan, Clifford E
Publicado: (2018)

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative
por: Kashtan, Clifford E., et al.
Publicado: (2012)

Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion
por: Adler, Liora, et al.
Publicado: (2002)

Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome
por: Gross, Oliver, et al.
Publicado: (2017)

Somatic Mosaicism in a Male Patient With X-linked Alport Syndrome
por: Bu, Lihong, et al.
Publicado: (2019)

Clinical trial recommendations for potential Alport syndrome therapies
por: Weinstock, B. André, et al.
Publicado: (2020)

The 2014 International Workshop on Alport Syndrome
por: Miner, Jeffrey H, et al.
Publicado: (2014)

Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder
por: Farhan, Bilal, et al.
Publicado: (2019)

Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria
por: Wang, Xiangling, et al.
Publicado: (2020)

Serum Monocyte Chemoattractant Protein-1 in Pancreatic Cancer
por: Sullivan, Jennifer, et al.
Publicado: (2011)

Role of Monocyte Chemoattractant Protein-1 in Myocardial Infarction
por: Morimoto, Hajime, et al.
Publicado: (2007)

Monocyte chemoattractant protein-1 in patients with peripheral arterial disease.
por: Petrkova, Jana, et al.
Publicado: (2004)

Urinary Concentration of Monocyte Chemoattractant Protein-1 in Idiopathic Glomerulonephritis: A Long-Term Follow-Up Study
por: Tofik, Rafid, et al.
Publicado: (2014)

Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1–deficient Mice
por: Lu, Bao, et al.
Publicado: (1998)

Alport Syndrome With Kidney Cysts Is Still Alport Syndrome
por: Savige, Judy, et al.
Publicado: (2021)

Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients
por: Hefler, L, et al.
Publicado: (1999)

Influence of HFE variants and cellular iron on monocyte chemoattractant protein-1
por: Mitchell, Ryan M, et al.
Publicado: (2009)

The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder
por: Pae, Chi-Un
Publicado: (2014)

Association between monocyte chemoattractant protein-1 and blood pressure in smokers
por: Komiyama, Maki, et al.
Publicado: (2017)

Role of monocyte chemoattractant protein‐1 in liver fibrosis with transient myeloproliferative disorder in down syndrome
por: Kobayashi, Kenichiro, et al.
Publicado: (2018)

Efficacy of Dapagliflozin in Adult Autosomal Recessive Alport Syndrome
por: Song, Zhuo-ran, et al.
Publicado: (2022)

Ethnic differences in urinary monocyte chemoattractant protein-1 and heparanase-1 levels in individuals with type 2 diabetes: the HELIUS study
por: van der Velden, Anouk I M, et al.
Publicado: (2022)

Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome
por: Franco-Peláez, Juan Antonio, et al.
Publicado: (2020)

Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer’s disease
por: Porcellini, Elisa, et al.
Publicado: (2013)

Serum monocyte chemoattractant protein-1 is a biomarker in patients with diabetes and periodontitis
por: Radhakrishnan, Preethi, et al.
Publicado: (2014)

Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity
por: Lim, Jun Pei, et al.
Publicado: (2015)

Monocyte chemoattractant protein-1 is not required for liver regeneration after partial hepatectomy
por: Wyler, Stephanie L., et al.
Publicado: (2016)

CCL2/Monocyte Chemoattractant Protein 1 and Parathyroid Hormone Action on Bone
por: Siddiqui, Jawed Akhtar, et al.
Publicado: (2017)

Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease
por: Santaella, Anna, et al.
Publicado: (2020)

Letter to the Editor: Characterization of Choriocapillaris and Choroidal Abnormalities in Alport Syndrome
por: Bosnar, Damir, et al.
Publicado: (2023)

Women and Alport syndrome
por: Rheault, Michelle N.
Publicado: (2011)

Alport's Syndrome in Pregnancy
por: Mehta, Suchita, et al.
Publicado: (2013)

Serum interferon-γ and urinary monocyte chemoattractant peptide-1 are important factors in the pathogenesis of immunoglobulin A nephropathy
por: Han, Sang Youb, et al.
Publicado: (2021)

Monocyte chemoattractant protein (MCP)-1 −2518 A/G SNP in Chinese Han patients with VKH syndrome
por: Hou, Shengping, et al.
Publicado: (2009)

An Alport Syndrome Journey: From Powerless to Empowered – A Patient Perspective
por: Bonebrake, Lisa
Publicado: (2023)

Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma
por: Takahashi, Yoshinobu, et al.
Publicado: (2017)

Monocyte Chemoattractant Protein-1 (MCP-1) Regulates Macrophage Cytotoxicity in Abdominal Aortic Aneurysm
por: Wang, Qiwei, et al.
Publicado: (2014)

Genetic diagnosis of Alport syndrome
por: Cheong, Hae Il
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0th4cs7sm8mr1hhb1bl6rf78l2